US EditionBioNTech's founding couple Sahin, Tuereci to leave to set up new venture
BioNTech founders will start a new firm focused on next-generation mRNA drugs, with BioNTech retaining a minority stake and rights to some mRNA technologies.
- Ugur Sahin and Özlem Türeci announced on March 10 that they will leave BioNTech by the end of 2026 to establish a new mRNA-focused startup.
- The company rose to prominence after developing Comirnaty with Pfizer, with sales peaking at nearly $38 billion and exceeding $20 billion in market value.
- BioNTech said it will transfer certain mRNA rights to the new unnamed biotech for a minority stake and milestone payments, and it will not provide ongoing capital support while its current drug development pipeline remains unaffected.
- Shares fell sharply, with stock dropping over 20% in early Tuesday trading, and Leerink Partners analyst Daina Graybosch warned the transition injects significant uncertainty.
- Sahin and Türeci will lead the new venture focused on next‑gen mRNA, and BioNTech said paperwork completion by the end of the first half supports 15 Phase 3 trials in cancer by the end of the year.
71 Articles
71 Articles
Uğur Şahin and Özlem Türeci are founding a new mRNA startup.
BioNTech Founders Leaving to Start Company Focused on mRNA Products
The co-founders of BioNTech, which helped create one of the most-used COVID-19 vaccines, are departing the German company to start their own firm. Drs. Ugur Sahin and Ozlem Tureci will be leaving BioNTech by the end of the year, BioNTech said on March 10. Sahin and Tureci, who are married, founded BioNTech in 2008 with Dr. Christopher Huber. The company helped develop the Pfizer-BioNTech COVID-19 vaccine, which utilizes messenger ribonucleic aci…
BioNTech founders Ugur Sahin and Özlem Türeci want to become pioneers again and leave their old company to start a new one. The new company is to focus on mRNA technologies of the next generation. BioNTech had recorded a billion-dollar loss in 2025. In the Corona years, BioNTech was home to billion-dollar profits thanks to the rapidly launched genetics and politically forced mass vaccinations. However, after the pandemic was no longer able to su…
Coverage Details
Bias Distribution
- 41% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
